

Diabetes, Body Mass Index, Vitamin Supplementation and Aotia/Microtia

**Martha M. Werler
Jane E. Sheehan
Allen A. Mitchell**

**Slone Epidemiology Center
Boston University**

**Presented at
Teratology Society
Annual Meeting**

**Vancouver, BC
June 30, 2004**

What do we know about the epidemiology of anotia/microtia?



**What do we know
about the epidemiology of
anotia/microtia?**

Not much!

Anotia/Microtia

The epidemiology of anotia and microtia. Harris, J, Kallen B, Robert E. J Med Genet 1996;33:809-13.

Mastroiacovo P, Corchia C, Botto LD, Lanni R, Zampino G, Fusco D. Epidemiology and genetics of microtia-anotia: a registry based study on over one million births. J Med Genet 1995;32:453-7.

Report from International Clearinghouse for Birth Defects Monitoring Systems. Congenital Malformations Worldwide. 1991. Elsevier.

Anotia/Microtia

What we do know:

**Prevalence is ~1-2 per
10,000 births**

Anotia/Microtia

Highest in:

Mexico	6.4
So. America	4.6
China	4.6
Calif – Hispanics	3.2
Calif – Asians	2.2
Ariz – Nat. Amer.	17.5

per 10,000 births

Anotia/Microtia

What we do know:

More common in males

Sex ratio: 1.6

~ 63 male : 37 female

Anotia/Microtia

Known causes:

Thalidomide

Isotretinoin

Genetic

Risk factor:

? Diabetes

Anotia/Microtia

Laterality:

35% bilateral

65% unilateral

**Bilateral more likely to have
associated malformations
than unilateral**

Anotia/Microtia

Associated malformations:

34-39% with associated major malformations, after excluding known chrom. anomalies

Anotia/Microtia

Associated malformations:

Facial cleft

Cardiac defect

Goldenhar S.

An/microphthalmia

Limb reduction defect

Renal anomaly

Holoprosencephaly

Anotia/Microtia

Associated defects occurring together:

**Anotia/microtia + holoprosencephaly +
an/microphthalmia**

**Anotia/microtia + neural tube defect +
facial cleft**

Holoprosencephaly – diabetes

Neural tube defects – diabetes

- body mass index**
- vitamin use**

Facial clefts – ?vitamin use

Are

- diabetes**
- body mass index**
- vitamin use**

associated with anotia/microtia risk?

Hemifacial Microsomia Study

Objective:

To identify vasoactive and other risk factors for hemifacial microsomia (HFM)

Hemifacial Microsomia Study

- **1997-2002**
- **Retrospective study**
- **Multicenter study – U.S. and Canada**
- **Cases from craniofacial centers**
- **Controls from case's pediatrician's office**

Hemifacial Microsomia Study

- Cases diagnosed with
 - Hemifacial microsomia
 - Facial asymmetry
 - Unilateral anotia/microtia
- < 3 years of age

Hemifacial Microsomia (HFM) Study

268 cases

238 with HFM

122 without an/microtia

116 with an/microtia

39 with unilateral an/microtia

**{ 155 anotia/
microtia cases**

854 non-malformed controls

Anotia/Microtia Study

Race/ethnicity	Cases n=155	Controls n=854
White, non-Hisp.	45.2%	65.2%
Hispanic	41.3%	18.5%
African-Amer.	5.2%	11.7%
Asian-Amer.	7.5%	3.6%
Native Amer.	1.9%	0.9%

Anotia/Microtia Study

Sex:

Sex ratio: 1.9

65% male vs. 52% male controls

Associated malformations:

75% with HFM

35% with defect other than HFM

Hemifacial Microsomia Study

- Mothers were interviewed by telephone
- Questions on
 - Demographic factors
 - Reproductive factors
 - Behaviors
 - Illnesses, medications, vitamins

Anotia/Microtia Study

**Diabetes: pre-existing or
gestational (lunar months 1 -5)**

**Body mass index: prepregnancy
height/meters²**

**Vitamin supplementation: Folic acid-
containing vitamin**

1st use in lunar month 1

1st use in lunar months 2 or 3

Anotia/Microtia Study

Diabetes	Cases n=155	Controls n=854
Overall	16 (10.3%)	12 (1.4%)
pre-preg.	8 (5.2%)	4 (0.5%)
dx LM1-3	3 (1.9%)	2 (0.2%)
dx LM 4-5	5 (3.2%)	6 (0.7%)

Anotia/Microtia Study

Body mass index (kg/m ²)	Cases n=155	Controls n=854
<19	19 (12.3%)	54 (6.3%)
19-23.9	64 (41.3%)	446 (52.2%)
24-27.9	27 (17.4%)	175 (20.5%)
28-31.9	21 (13.5%)	87 (10.2%)
≥32	13 (8.4%)	72 (8.4%)
Unknown	11 (7.1%)	20 (2.3%)

Anotia/Microtia Study

F.A. 1 st use in	Cases n=155	Controls n=854
LM 1	44 (28.4%)	275 (32.2%)
LM 2 or 3	70 (45.2%)	454 (53.2%)
Later or none	41 (26.5%)	125 (14.6%)

Anotia/Microtia Study

Risk factor	Odds ratio [@]	95% CI
Diabetes	6.3	2.7-14.9
BMI: <19*	2.3	1.2-4.3
BMI: \geq 28*	1.2	0.7-2.1
F.A. LM 1-3	0.7	0.4-1.1

[@]Adjusted for maternal age, education, income, race, and
gestations.

*ref. category 19-23.9

**Does vitamin use modify the
effect of diabetes on
anotia/microtia risk?**

Does vitamin use modify the effect of diabetes on anotia/microtia risk?

Diabetes and vitamins?	<u>No</u>	<u>Yes</u>
Birth defects	3.9*	0.15
Hydrocephaly	2.5	0
Heart defects	4.5*	1.0
Respiratory tract	6.8	0
Pyloric stenosis	4.0	0

*p<.05

Anotia/Microtia Study

Diabetes	Cases	Controls
+ F.A. use	11 (7.1%)	10 (1.2%)
OR (95% CI)*	5.5 (2.0-15.0)	
- F.A. use	5 (12.8%)	2 (1.7%)
OR (95% CI)*	9.8 (1.1-87.0)	

*Adjusted for maternal age, education, income, race, and # gestations

Anotia/Microtia Study

Limitations:

Study designed to capture HFM cases

Bilateral cases not ascertained

**Ascertainment of anotia/microtia cases
is not likely to be complete**

Anotia/Microtia Study

Limitations:

**Would cases born to women with
diabetes**

high or low BMI

vitamin supplementation

be more or less likely to be in the study?

Anotia/Microtia Study

Strengths:

Ethnic/race and sex distributions in present study were similar to CBDMP

Anotia/Microtia Study

Limitations:

Retrospective recall

Imperfect measure of diabetes

Anotia/Microtia Study

Conclusions:

Our findings confirm those from Italy: diabetes appears to increase anotia/microtia risk

Anotia/Microtia Study

Conclusions:


Our findings suggest that, unlike NTDs, obesity does not increase anotia/microtia risk

Rather, our findings suggest women with low pre-pregnant BMI might have an increased risk

Anotia/Microtia Study

Conclusions:

Our findings suggest that folic acid-containing vitamin supplementation does not attenuate the effects of diabetes on anotia/microtia risk.



Anotia/Microtia

Sideness:

65% are unilateral

61% are right-sided

Anotia/Microtia Study

Body mass index (kg/m²)	Cases <u>n=155</u>	Controls <u>n=854</u>
<19	(12.3%)	(6.3%)
19-23.9	(41.3%)	(52.2%)
24-27.9	(17.4%)	(20.5%)
28-31.9	(13.5%)	(10.2%)
≥32	(8.4%)	(8.4%)
Unknown	(7.1%)	(2.3%)



www.emedicine.com/ped/topic3003.htm



www.emedicine.com/ped/topic3003.htm